ArticlePloS one2010
Mycobacterium bovis-BCG vaccination induces specific pulmonary transcriptome biosignatures in mice.
Article in PloS one, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Unleashing the power of the BCG vaccine in modulating viral immunity through heterologous protection: A scoping review.Human vaccines & immunotherapeutics · 2025Article
- Backtranslation of human RNA biosignatures of tuberculosis disease risk into the preclinical pipeline is condition dependent.mSphere · 2025Article
- Advances in understanding the role of pentraxin-3 in lung infections.Frontiers in immunology · 2025Review
- The Cellular and Transcriptomic Early Innate Immune Response to BCG Vaccination in Mice.Cells · 2024Article
- Transcriptional signatures measured in whole blood correlate with protection against tuberculosis in inbred and outbred mice.PloS one · 2023Article
- Recent developments in systems biology and genetic engineering toward design of vaccines for TB.Critical reviews in biotechnology · 2022Review
- A century of BCG vaccination: Immune mechanisms, animal models, non-traditional routes and implications for COVID-19.Frontiers in immunology · 2022Review
- Contribution and Future of High-Throughput Transcriptomics in Battling Tuberculosis.Frontiers in microbiology · 2022Review
- CD4+CCR6+ T cells dominate the BCG-induced transcriptional signature.EBioMedicine · 2021Article
- Is mapping the BCG vaccine-induced immune responses the key to improving the efficacy against tuberculosis?Journal of internal medicine · 2020Review
- Obese communities among the best predictors of COVID-19-related deaths.Cardiovascular endocrinology & metabolism · 2020Article
- Cell Differentiation Degree as a Factor Determining the Role for Different T-Helper Populations in Tuberculosis Protection.Frontiers in immunology · 2019Review
- Gene expression profiling identifies candidate biomarkers for active and latent tuberculosis.BMC bioinformatics · 2016Article
- A novel murine cytomegalovirus vaccine vector protects against Mycobacterium tuberculosis.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Article
- Article
- Harnessing local and systemic immunity for vaccines against tuberculosis.Mucosal immunology · 2014Review
- Development of an unbiased antigen-mining approach to identify novel vaccine antigens and diagnostic reagents for bovine tuberculosis.Clinical and vaccine immunology : CVI · 2013Article
- Article
- Environmental effects on protection against Mycobacterium tuberculosis after immunization with Ad85A.Vaccine · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the present study, we applied microarray technology to define biosignatures by microarray transcriptome analysis in lung and spleen samples after BCG vaccination and M. bovis infection of BALB/c mice. The aims were two-fold, namely to define biosignatures that could predict vaccine success before challenge, and biomarker patterns that correlated with anamnestic protective responses following exposure to virulent M. bovis. Further, these biosignatures should be detectable without in vitro antigenic challenge. PRINCIPAL
findingsAfter BCG vaccination, we defined a specific pulmonary gene expression signature related to the connective tissue development and function network that predicted vaccine success before M. bovis challenge. In addition, a Th17-related cytokine profile was found that correlated with vaccine-induced protective immunity following infection with virulent M. bovis in the lung as well as additional genes that were up-regulated in the spleens of vaccinated animals post-infection related to neutrophil biology and inflammation.
conclusionsThis study has therefore prioritized both biomarkers predicting vaccination success before challenge and bio-signatures that are potentially associated with protective immune responses that will be useful to evaluate future vaccine candidates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.